Literature DB >> 31472915

Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.

Sebastian Mondaca1, Hooman Yarmohammadi2, Nancy E Kemeny3.   

Abstract

Locally advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma are associated with a grim prognosis. The development of highly effective systemic therapies for these tumors has been challenging; however, numerous locoregional treatment alternatives have emerged, including transarterial hepatic embolization (TAE), transarterial chemoembolization (TACE), drug-eluting bead TACE (DEB-TACE), hepatic arterial infusion chemotherapy (HAI), radioembolization, and stereotactic body radiation therapy. Although there is potential for long-term disease control for these therapies, the evidence to guide adequate patient selection and choose among different treatment alternatives is still limited. This review focuses on the rationale and data supporting TAE, TACE, DEB-TACE, and HAI in hepatobiliary cancers.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoembolization; Cholangiocarcinoma; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31472915      PMCID: PMC8240360          DOI: 10.1016/j.soc.2019.06.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  74 in total

Review 1.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

2.  Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Authors:  Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

3.  Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.

Authors:  Maurizio Cantore; Andrea Mambrini; Giammaria Fiorentini; Carla Rabbi; Donatella Zamagni; Roberto Caudana; Cristina Pennucci; Franco Sanguinetti; Mirko Lombardi; Nicola Nicoli
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

Review 4.  Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.

Authors:  Marco Massani; Cristina Nistri; Cesare Ruffolo; Roberta Bonariol; Bruno Pauletti; Luca Bonariol; Ezio Caratozzolo; Giovanni Morana; Nicolò Bassi
Journal:  Updates Surg       Date:  2015-12

Review 5.  Clinical pharmacology of hepatic arterial chemotherapy.

Authors:  W D Ensminger; J W Gyves
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

6.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

7.  Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Authors:  Katerina Malagari; Mary Pomoni; Alexis Kelekis; Anastasia Pomoni; Spyros Dourakis; Themis Spyridopoulos; Hippokratis Moschouris; Emmanouil Emmanouil; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-24       Impact factor: 2.740

8.  Intrahepatic chemotherapy for unresectable hepatocellular carcinoma.

Authors:  R Doci; P Bignami; F Bozzetti; G Bonfanti; R Audisio; M Colombo; L Gennari
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

9.  Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study.

Authors:  Andrea Mambrini; Alfredo Guglielmi; Paola Pacetti; Calogero Iacono; Tito Torri; Alessio Auci; Nicola Nicoli; Massimo Orlandi; Stefano Guadagni; Giammaria Fiorentini; Maurizio Cantore
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more
  1 in total

1.  Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.

Authors:  Xiaoliang Xu; Yingfan Mao; Yanqiu Tang; Yang Liu; Cailin Xue; Qi Yue; Qiaoyu Liu; Jincheng Wang; Yin Yin
Journal:  Comput Math Methods Med       Date:  2022-02-21       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.